secwatch / observer

CrossAmerica Partners LP — fact timeline

Source-grounded facts extracted from CrossAmerica Partners LP's SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.

CAPL CrossAmerica Partners LP JSON
Earnings Releases

CrossAmerica Partners LP reported first quarter ended March 31, 2026 results: net income Net Income of $10.7 million.

“CrossAmerica Partners LP Reports First Quarter 2026 Results - Reported First Quarter of 2026 Net Income of $10.7 million, Adjusted EBITDA of $35.1 million and Distributable Cash Flow of $21.5 million”
Earnings Releases

CrossAmerica Partners LP reported quarter ended March 31, 2024 results: net income Net Loss of $17.5 million.

“Reported First Quarter 2024 Net Loss of $17.5 million that includes a $15.9 million loss on lease terminations with Applegreen, Adjusted EBITDA of $23.6 million and Distributable Cash Flow of $11.7 million compared to a Net Loss of $1.0 million, Adjusted EBITDA of $31.7 million and Distributable Cash Flow of $19.1 million for the First Quarter 2023”
Earnings Releases

CrossAmerica Partners LP reported Full Year 2023 results: net income $42.6 million.

“Generated Full Year 2023 Net Income of $42.6 million, Adjusted EBITDA of $165.8 million and Distributable Cash Flow of $116.7 million compared to Full Year 2022 Net Income of $63.7 million, Adjusted EBITDA of $179.8 million and Distributable Cash Flow of $140.9 million”
Earnings Releases

CrossAmerica Partners LP reported Fourth Quarter 2023 results: net income $16.7 million.

“Reported Fourth Quarter 2023 Net Income of $16.7 million, Adjusted EBITDA of $47.6 million and Distributable Cash Flow of $35.8 million compared to Fourth Quarter 2022 Net Income of $17.1 million, Adjusted EBITDA of $44.3 million and Distributable Cash Flow of $33.3 million”

Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.